Pyxis Oncology, Inc.

PYXS

Healthcare|Biotechnology|US

$1.66

+0.05 (+3.11%)

DCF Value

$1.70

Tangible Book / Share

$0.49

Cash / Share

$0.67

Next Earnings Report

Mar 22, 2027

EPS est. -$0.26

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Oct 1, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Apr 2027

Est. completion

P1Solid Tumor

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117n=330

Dec 2027

Est. completion

P1P2Advanced Solid Tumors

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT06795412n=220

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

May 2026

Study of PYX-106 in Solid Tumors

NCT05718557

Recent Press Releases

Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)

Nov 5, 2026 · GlobeNewsWire

Pyxis Oncology to Participate in Upcoming Investor Conferences

Oct 28, 2026 · GlobeNewsWire

Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 27, 2026 · GlobeNewsWire

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

Oct 2, 2026 · GlobeNewsWire

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

Sep 30, 2026 · GlobeNewsWire

Pyxis Oncology Announces Proposed Public Offering

Sep 29, 2026 · GlobeNewsWire

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Sep 9, 2026 · GlobeNewsWire

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Sep 8, 2026 · GlobeNewsWire

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

Sep 8, 2026 · GlobeNewsWire

Pyxis Oncology to Participate in Upcoming Investor Conferences

Sep 1, 2026 · GlobeNewsWire

SEC Filings (71)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	10-Q	Quarterly report	Document Index
Nov 5, 2026	8-K	Material event	Document Index
Nov 3, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Oct 21, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Oct 9, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Oct 9, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Oct 5, 2026	SC 13G	Passive 5%+ stake	Document Index
Oct 2, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Oct 1, 2026	8-K	Material event	Document Index
Oct 1, 2026	424B5	Offering prospectus	Document Index
Sep 29, 2026	424B5	Offering prospectus	Document Index
Sep 29, 2026	424B5	Offering prospectus	Document Index
Sep 9, 2026	8-K	Material event	Document Index
Sep 8, 2026	8-K	Material event	Document Index
Aug 28, 2026	424B2	Offering prospectus	Document Index
Aug 27, 2026	EFFECT		Document Index
Aug 20, 2026	S-3	Shelf registration	Document Index
Aug 13, 2026	10-Q	Quarterly report	Document Index
Aug 13, 2026	8-K	Material event	Document Index
Jul 10, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 2, 2026	8-K	Material event	Document Index
Jul 2, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jun 15, 2026	8-K	Material event	Document Index
May 14, 2026	10-Q	Quarterly report	Document Index
May 14, 2026	8-K	Material event	Document Index
Apr 30, 2026	ARS	Annual report to holders	Document Index
Apr 30, 2026	DEFA14A	Proxy / shareholder vote	Document Index
Apr 30, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Apr 30, 2026	8-K/A	Material event	Document Index
Mar 23, 2026	S-8	Employee stock plan	Document Index
Mar 23, 2026	10-K	Annual report	Document Index
Mar 23, 2026	8-K	Material event	Document Index
Feb 9, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Feb 6, 2026	8-K	Material event	Document Index
Dec 18, 2025	8-K	Material event	Document Index
Dec 9, 2025	EFFECT		Document Index
Nov 26, 2025	S-3	Shelf registration	Document Index
Nov 3, 2025	10-Q	Quarterly report	Document Index
Nov 3, 2025	8-K	Material event	Document Index
Oct 14, 2025	SC 13G/A	Passive 5%+ stake	Document Index